| Literature DB >> 35053180 |
Brita Zilg1, Kanar Alkass1, Robert Kronstrand2, Sören Berg3, Henrik Druid1.
Abstract
Vitreous fluid is commonly collected for toxicological analysis during forensic postmortem investigations. Vitreous fluid is also often analyzed for potassium, sodium, chloride and glucose for estimation of time since death, and for the evaluation of electrolyte imbalances and hyperglycemia, respectively. Obtaining such results in the early phase of a death investigation is desirable both in regard to assisting the police and in the decision-making prior to the autopsy. We analyzed vitreous fluid with blood gas instruments to evaluate/examine the possible impact of different sampling and pre-analytical treatment. We found that samples from the right and left eye, the center of the eye as well as whole vitreous samples gave similar results. We also found imprecision to be very low and that centrifugation and dilution were not necessary when analyzing vitreous samples with blood gas instruments. Similar results were obtained when analyzing the same samples with a regular multi-analysis instrument, but we found that such instruments could require dilution of samples with high viscosity, and that such dilution might impact measurement accuracy. In conclusion, using a blood gas instrument, the analysis of postmortem vitreous fluid for electrolytes and glucose without sample pretreatment produces rapid and reliable results.Entities:
Keywords: electrolytes; forensic medicine; glucose; postmortem; vitreous
Mesh:
Substances:
Year: 2021 PMID: 35053180 PMCID: PMC8773483 DOI: 10.3390/biom12010032
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Within-series and between-series imprecision of ABL90 flex instrument.
| Within-Series Imprecision | Between-Series Imprecision | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glucose | Potassium | Glucose | Potassium | ||||||||||
| Solution 1 | Solution 2 | Solution 3 | Solution 2 | 10 mmol/L | 30 mmol/L | Solution 1 | Solution 2 | Solution 3 | Solution 2 | 10 mmol/L | 30 mmol/L | ||
| Mean | 4.26 | 10.55 | 15.13 | 4.40 | 10.00 | 29.96 | Mean | 4.26 | 10.61 | 15.23 | 4.41 | 9.75 | 29.49 |
| SD | 0.07 | 0.09 | 0.15 | 0.00 | 0.00 | 0.07 | SD | 0.07 | 0.23 | 0.31 | 0.04 | 0.32 | 0.55 |
| CV% | 1.75 | 0.88 | 0.98 | 0.00 | 0.00 | 0.25 | CV% | 1.75 | 2.16 | 2.01 | 0.80 | 3.24 | 1.87 |
| Bias% | −3.85 | −4.81 | −3.86 | 2.33 | 0.00 | −0.12 | Bias% | −3.85 | −4.25 | −3.23 | 2.62 | −2.50 | −1.71 |
Figure 1Comparison results using ABL90 flex and ABL700.
Figure 2Comparison of ABL90 flex and Beckman Coulter AU5800.
Figure 3Comparison of ABL90 flex and ICP-MS.
Figure 4Comparison of Beckman Coulter AU5800 and ICP-MS.
Impact of cells and centrifugation. Means and standard deviations of the concentrations of potassium, sodium and chloride.
| Cell Number (Cells/mL) | Untreated (mmol/L) | Supernatant (mmol/L) | Pellet (mmol/L) | |
|---|---|---|---|---|
| K+ | >100,000 ( | 19.8 ± 3.8 | 19.9 ± 3.7 | 19.8 ± 3.4 |
| <20,000 ( | 16.9 ± 3.5 | 17.0 ± 3.5 | 17.2 ± 3.6 | |
| Na+ | >100,000 ( | 120.8 ± 13.1 | 122 ± 12.9 | 123 ± 12.7 |
| <20,000 ( | 129.1 ± 8.7 | 130 ± 9.0 | 132 ± 9.1 | |
| Cl− | >100,000 ( | 104 ± 10.9 | 104 ± 11.2 | 109 ± 13.2 |
| <20,000 ( | 111 ± 10.8 | 111 ± 11.1 | 114 ± 11.1 |
Figure 5Comparison of undiluted and diluted samples, n = 29.
Effect of addition of (a) hyaluronidase to postmortem vitreous samples and (b) sodium hyaluronate to water solutions of electrolytes.
| ( | |||||||||||||
|
|
|
|
|
|
| ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
| ||
| 1 | 11 | 130 | 107 | 0.92 | 0.92 | 0.93 | 1 | 10.9 | 129 | 106 | 0.92 | 0.91 | 0.92 |
| 2 | 11.6 | 130 | 96 | 0.94 | 0.93 | 0.92 | 2 | 11.6 | 129 | 96 | 0.94 | 0.92 | 0.92 |
| 3 | 7.8 | 127 | 110 | 0.93 | 0.92 | 0.92 | 3 | 7.8 | 127 | 110 | 0.93 | 0.92 | 0.92 |
| 4 | 13 | 122 | 107 | 0.92 | 0.91 | 0.91 | 4 | 13.1 | 122 | 107 | 0.93 | 0.91 | 0.91 |
| 5 | 10.6 | 119 | 106 | 0.92 | 0.92 | 0.93 | 5 | 10.5 | 118 | 105 | 0.91 | 0.91 | 0.92 |
| 6 | 11.9 | 126 | 111 | 0.92 | 0.91 | 0.92 | 6 | 11.9 | 126 | 111 | 0.92 | 0.91 | 0.92 |
| 7 | 16.3 | 122 | 105 | 0.93 | 0.92 | 0.92 | 7 | 16.3 | 122 | 106 | 0.93 | 0.92 | 0.93 |
| 8 | 21.1 | 95 | 77 | 0.92 | 0.91 | 0.92 | 8 | 21 | 95 | 77 | 0.92 | 0.91 | 0.92 |
| ( | |||||||||||||
|
|
|
|
|
|
| ||||||||
| 10 µL DDH2O | 9.7 | 110 | 113 | 111 | 114 | ||||||||
| 10 µL DDH2O | 9.7 | 110 | 113 | 111 | 114 | ||||||||
| 20 µL DDH2O | 9.6 | 109 | 112 | 111 | 114 | ||||||||
| 20 µL DDH2O | 9.6 | 108 | 112 | 110 | 114 | ||||||||
| 50 µL DDH2O | 9.4 | 105 | 109 | 110 | 114 | ||||||||
| 50 µL DDH2O | 9.4 | 105 | 109 | 110 | 114 | ||||||||
| 100 µL DDH2O | 9.0 | 101 | 104 | 111 | 114 | ||||||||
| 100 µL DDH2O | 8.9 | 100 | 104 | 110 | 114 | ||||||||
| 10 µL hyaluronate | 9.7 | 111 | 115 | 112 | 116 | ||||||||
| 10 µL hyaluronate | 9.7 | 111 | 115 | 112 | 116 | ||||||||
| 20 µL hyaluronate | 9.7 | 112 | 115 | 114 | 117 | ||||||||
| 20 µL hyaluronate | 9.7 | 112 | 115 | 114 | 117 | ||||||||
| 50 µL hyaluronate | 9.4 | 113 | 116 | 119 | 122 | ||||||||
| 50 µL hyaluronate | 9.4 | 113 | 116 | 119 | 122 | ||||||||
| 100 µL hyaluronate | 9.1 | 115 | 117 | 127 | 129 | ||||||||
| 100 µL hyaluronate | 9.0 | 115 | 117 | 127 | 129 | ||||||||
Figure 6Comparison of whole and central vitreous.
Figure 7Comparison of samples taken from center of the right and left eye, n = 16.
Figure 8Comparison of actual concentration and calculated concentration (vitreous + spike).
Figure 9Comparison of samples not vortexed (day 1) and vortexed (day 2), n = 13.